Prevalence of aspirin and clopidogrel resistance in neurovascular stenting: a single-center experience

Abstract

Objectives: The objective of this study was to determine the frequency of aspirin and clopidogrel resistance of patients undergoing neurovascular stenting procedure in the interventional radiology unit.

Methods: The Multiplate® Analyzer (Roche Diagnostics, Germany) test data of 250 patients who underwent carotid or intracranial artery stenting due to atherosclerotic stenosis or treatment of intracranial aneurysms between 2013-2017 in the Interventional Radiology Unit of our hospital were evaluated retrospectively to detect the aspirin and clopidogrel resistance. Aspirin or clopidogrel resistance defined as the higher AUC value than 40U and 46U, respectively. The patients who did not have a result of the Multiplate® test; had anemia, known coagulation disorder or thrombocytopenia were excluded.

Results: Among the 172 patients who met the inclusion criteria, 59 (34.3%) were those who had an intracranial stent during aneurysm treatment, and 113 (65.7%) had carotid stenting due to atherosclerotic stenosis. The prevalence of aspirin resistance was 9.4% (16/170) whereas that of clopidogrel resistance was 23.8% (41/172). Among the patients with atherosclerotic stenosis, aspirin resistance accounting for 3.6%, and clopidogrel resistance was 23.0%. Furthermore, the resistance in the patients with stent-assisted coiling for aneurysm treatment was 20.7% for aspirin and 25.4% for clopidogrel.

Conclusions: In our study, the prevalence of aspirin resistance was found 9.4% and clopidogrel resistance 23.8% in patients who had neurovascular stenting. The effect of this condition on clinical outcomes in these patients should be investigated by randomized controlled trials.

Keywords

• Neurovascular stenting
• Aspirin resistance
• Clopidogrel resistance
• Antiplatalet resistance
• Multiplate test

References

1. 1. Fiorella D, Thiabolt L, Albuquerque FC, Deshmukh VR, McDougall CG, Rasmussen PA. Antiplatelet therapy in neuroendovascular therapeutics. Neurosurg Clin N Am 2005;16:517-40.
2. 2. Qureshi AI, Luft AR, Sharma M, Guterman LR, Hopkins LN. Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: Part II--Clinical aspects and recommendations. Neurosurgery 2000;46:1360-75; discussion 1375-6.
3. 3. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33.
4. 4. Oran I, Cinar C, Bozkaya H, Korkmaz M. Tailoring platelet inhibition according to multiple electrode aggregometry decreases the rate of thrombotic complications after intracranial flow-diverting stent implantation. J Neurointerv Surg 2015;7:357-62.
5. 5. Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardiovasc Dis 2009;52:141-52.
6. 6. Price MJ. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention. JAMA 2011;305:1097.
7. 7. Collet J-P, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-9.
8. 8. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents. J Am Coll Cardiol 2012;59:2159-64.

9. 9. Guirgis M, Thompson P, Jansen S. Review of aspirin and clopidogrel resistance in peripheral arterial disease. J Vasc Surg 2017;66:1576-86.
10. 10. Fiolaki A, Katsanos AH, Kyritsis AP, Papadaki S, Kosmidou M, Moschonas IC, et al. High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: a systematic review and meta-analysis. J Neurol Sci 2017;376:112-6.
11. 11. Asai T, Miyachi S, Izumi T, Matsubara N, Haraguchi K, Yamanouchi T, et al. Relationship between low response to clopidogrel and periprocedural ischemic events with coil embolization for intracranial aneurysms. J Neurointerv Surg 2016;8:752-5.
12. 12. Drazin D, Choulakian A, Nuno M, Kornbluth P, Alexander MJ. Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. J Neurointerv Surg 2011;3:177-81.
13. 13. Lee DH, Arat A, Morsi H, Shaltoni H, Harris JR, Mawad ME. Dual antiplatelet therapy monitoring for neurointerventional procedures using a Point-of-Care platelet function test: a single-center experience. Am J Neuroradiol 2008;29:1389-94.
14. 14. Delgado Almandoz JE, Crandall BM, Scholz JM, Fease JL, Anderson RE, Kadkhodayan Y, et al. Pre-procedure P2Y12 reaction units value predicts perioperative thromboembolic and hemorrhagic complications in patients with cerebral aneurysms treated with the Pipeline Embolization Device. J Neurointerv Surg 2013;5 Suppl 3:iii3-10.
15. 15. Fifi JT, Brockington C, Narang J, Leesch W, Ewing SL, Bennet H, et al. Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. AJNR Am J Neuroradiol 2013;34:716-20.
16. 16. Kashiwazaki D, Kuwayama N, Akioka N, Hayakawa Y, Kuroda S. The roles and issues of P2Y12 percent inhibition assessed by VerifyNow assay for patients undergoing neurointervention: a prospective study. J Stroke Cerebrovasc Dis 2014;23:1830-6.
17. 17. Koerner H, Derveaux C, Alexandrou M, Graeber S, Roth C, Papanagiotou P, et al. Do clopidogrel nonresponders have an increased risk of adverse events during supra-aortal angioplasty and stenting? Stroke Res Treat 2012;2012:904534.
18. 18. Müller-Schunk S, Linn J, Peters N, Spannagl M, Deisenberg M, Brückmann H, et al. Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting. Am J Neuroradiol 2008;29:786-91.
19. 19. Pandya D, Fitzsimmons B, Wolfe T, Hussain S, Lynch J, Ortega-Gutierrez S, et al. Measurement of antiplatelet inhibition during neurointerventional procedures: the effect of antithrombotic duration and loading dose. J Neuroimaging 2010;20:64-9.
20. 20. Wong P, Tesoro E, Aletich V, Alaraj A. Accumetrics-based clopidogrel dosing in endovascular neurosurgery. Neurol Res 2015;37:998-1005.
21. 21. Song J, Shin YS. Antiplatelet drug resistance did not increase the thromboembolic events after stent-assisted coiling of unruptured intracranial aneurysm: a single center experience of 99 cases. Neurol Sci 2017;38:879-85.
22. 22. Nordeen JD, Patel A V, Darracott RM, Johns GS, Taussky P, Tawk RG, et al. Clopidogrel resistance by P2Y12 platelet function testing in patients undergoing neuroendovascular procedures: incidence of ischemic and hemorrhagic complications. J Vasc Interv Neurol 2013;6:26-34.
23. 23. Heller RS, Dandamudi V, Lanfranchi M, Malek AM. Effect of antiplatelet therapy on thromboembolism after flow diversion with the Pipeline Embolization Device. J Neurosurg 2013;119:1603-10.
24. 24. Tan LA, Keigher KM, Munich SA, Moftakhar R, Lopes DK. Thromboembolic complications with Pipeline Embolization Device placement: impact of procedure time, number of stents and pre-procedure P2Y12 reaction unit (PRU) value. J Neurointerv Surg 2015;7:217-21.
25. 25. Nishi H, Nakahara I, Matsumoto S, Hashimoto T, Ohta T, Sadamasa N, et al. Platelet reactivity and hemorrhage risk in neurointerventional procedures under dual antiplatelet therapy. J Neurointerv Surg 2016;8:949-53.
26. 26. Reavey-Cantwell JF, Fox WC, Reichwage BD, Fautheree GL, Velat GJ, Whiting JH, et al. Factors associated with aspirin resistance in patients premedicated with aspirin and clopidogrel for endovascular neurosurgery. Neurosurgery 2009;64:890-6.
27. 27. Ryu D-S, Hong C-K, Sim Y-S, Kim C-H, Jung J-Y, Joo J-Y. Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointervention. J Korean Neurosurg Soc 2010;48:319.
28. 28. Flechtenmacher N, Kämmerer F, Dittmer R, Budde U, Michels P, Röther J, et al. Clopidogrel resistance in neurovascular stenting: correlations between light transmission aggregometry, VerifyNow, and the Multiplate. Am J Neuroradiol 2015;36:1953-8.
29. 29. Podlasek A, Al Sultan AA, Assis Z, Kashani N, Goyal M, Almekhlafi MA. Outcome of intracranial flow diversion according to the antiplatelet regimen used: a systematic review and meta-analysis. J Neurointerv Surg 2020;12:148-55.
30. 30. Oran I, Cinar C, Gok M, Duzgun F. Aggregometry response to half-dose prasugrel in flow-diverting stent implantation. Clin Neuroradiol 2020;30:463–9.
31. 31. Oran I, Cinar C. Nöroendovasküler Girişimsel Tedavilerde Anti-trombotik İlaç Kullanımı. Türk Radyoloji Semin 2018;6:11-26.
32. 32. Shim EJ, Ryu C-W, Park S, Lee HN, Shin HS, Kim S-B. Relationship between adverse events and antiplatelet drug resistance in neurovascular intervention: a meta-analysis. J Neurointerv Surg 2018;10:942-8.